PATENT CLAIM ANALYSIS

Application Number: 15775312
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "234500"]

Abstract:
The present invention relates to a 7-azaindolin-2-one derivative or a pharmaceutically acceptable salt thereof, and the 7-azaindolin-2-one derivative or the pharmaceutically acceptable salt thereof can be favorably used as a medicinal material for inhibiting cancer growth and cancer metastasis.

Claim (Index 13):
The method according to  claim 12 , wherein the cancer is any one selected from the group consisting of lung cancer, breast cancer, bladder cancer, bone cancer, thyroid cancer, parathyroid cancer, rectal cancer, prostate cancer, renal cancer, laryngopharyngeal cancer, larynx cancer, esophageal cancer, pancreatic cancer, colorectal cancer, stomach cancer, tongue cancer, skin cancer, brain tumor, uterine cancer, head or neck cancer, gallbladder cancer, oral cancer, colon cancer, anal cancer, tumors of the central nervous system and liver cancer.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 93.0
- Lexical Diversity: 1.41379
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13196391', '12451466', '12223180', '13945924', '13106076']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7966597418327145
- 35 USC 102 Novelty (BERT): 0.524581625578414
- Combined Prediction Score: 0.7694519302072844
- Mean Citation Score: 311.092622
- Max Citation Score: 313.8167
- Similarity Product: 219.6145426889181

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test